Daunorubicin (NSC-82151), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) combination therapy for advanced adult acute leukemia.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000009:adverse effects / Q000627:therapeutic use*; D003630:Daunorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination / Q000009:adverse effects; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use*
D003561:Cytarabine; D014750:Vincristine; D011241:Prednisone; D003630:Daunorubicin